Introduction: Strong indirect evidence implicates the involvement of advanced glycation end products (AGEs) and vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic retinal edema and ischemia. Preliminary Data: (l) Retinal VEGF expression is increased in early background diabetic retinopathy. (2) Exogenous VEGF produces many of the changes of diabetic retinopathy, including retinal edema and ischemia. (3) Glucose-derived AGEs increase retinal cell VEGF expression in vitro and in vivo. (4) VEGF is the primary endothelial cell mitogen induced by AGEs. (5) Retinal vascular leakage occurs early in experimental diabetic retinopathy and coincides with the increased expression of VEGF. Hypotheses: (1) VEGF is causal for the increased vascular permeability of diabetic retinopathy. (2) Endogenous AGEs increase VEGF expression in early diabetic retinopathy. (3) AGEs, through VEGF, are operative in the development of acellular capillaries, endothelial cell proliferation, pericyte death and microaneurysms.
Specific Aims : (1) To demonstrate that AGE-induced increases in retinal VEGF expression are causal for the increased retinal vascular permeability of diabetes. (2) To demonstrate that the long-term dissolution of AGE crosslinks prevents retinal VEGF upregulation and many of the anatomic alterations of diabetic retinopathy. Significance: Studies aimed at understanding the mechanisms of diabetic retinal edema and ischemia, two major causes of vision loss, will provide important information that could lead to effective treatments for diabetic retinopathy.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
1R01EY012611-01
Application #
2760291
Study Section
Special Emphasis Panel (ZRG2-NMS (02))
Project Start
1999-04-01
Project End
2002-03-31
Budget Start
1999-04-01
Budget End
2000-03-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Usui, Tomohiko; Ishida, Susumu; Yamashiro, Kenji et al. (2004) VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45:368-74
Joussen, Antonia M; Poulaki, Vassiliki; Le, Minh Ly et al. (2004) A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 18:1450-2
Yamashiro, Kenji; Tsujikawa, Akitaka; Ishida, Susumu et al. (2003) Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol 163:253-9
Carrasquillo, Karen G; Ricker, Joseph A; Rigas, Ioannis K et al. (2003) Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci 44:290-9
Moore, Tara C B; Moore, Jonathan E; Kaji, Yuichi et al. (2003) The role of advanced glycation end products in retinal microvascular leukostasis. Invest Ophthalmol Vis Sci 44:4457-64
Ishida, Susumu; Yamashiro, Kenji; Usui, Tomohiko et al. (2003) Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med 9:781-8
Joussen, Antonia M; Poulaki, Vassiliki; Qin, Wenying et al. (2002) Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 160:501-9
Joussen, Antonia M; Poulaki, Vassiliki; Tsujikawa, Akitaka et al. (2002) Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160:1683-93
Poulaki, Vassiliki; Qin, Wenying; Joussen, Antonia M et al. (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 109:805-15
Moore, J E; McMullen, C B T; Mahon, G et al. (2002) The corneal epithelial stem cell. DNA Cell Biol 21:443-51

Showing the most recent 10 out of 20 publications